552 related articles for article (PubMed ID: 19741229)
1. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
2. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
5. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major EO
N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
[No Abstract] [Full Text] [Related]
6. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
Kleinschmidt-DeMasters BK; Tyler KL
N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
[TBL] [Abstract][Full Text] [Related]
7. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
8. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Warnke C; Adams O; Kieseier BC
N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
[No Abstract] [Full Text] [Related]
9. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
10. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Warnke C; Adams O; Hartung HP; Kieseier BC
Ann Neurol; 2011 Jan; 69(1):215-6; author reply 216. PubMed ID: 21280097
[No Abstract] [Full Text] [Related]
11. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
Kleiter I; Schröder M; Lürding R; Schuierer G; Clifford DB; Bogdahn U; Steinbrecher A; Pöschl P
Mult Scler; 2010 Jun; 16(6):749-53. PubMed ID: 20453014
[TBL] [Abstract][Full Text] [Related]
12. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
13. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
14. Immunological and clinical consequences of treating a patient with natalizumab.
Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
[TBL] [Abstract][Full Text] [Related]
15. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
18. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
20. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]